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Abstract 
Background – DWI-FLAIR mismatch was suggested to identify stroke patients with unknown 
time of symptom onset likely to be within the time window for thrombolysis.  
Aims – We aimed to study clinical characteristics associated with DWI-FLAIR mismatch in 
patients with unknown onset stroke. 
Methods – We analysed baseline MRI and clinical data from patients with acute ischemic 
stroke proven by DWI from WAKE-UP, an investigator-initiated, randomised, placebo-
controlled trial of MRI based thrombolysis in stroke patients with unknown time of symptom 
onset. Clinical characteristics were compared between patients with and without DWI-FLAIR 
mismatch. 
Results – Of 699 patients included, 418 (59.8%) presented with DWI-FLAIR mismatch.  A 
shorter delay between last seen well and symptom recognition (p=0.0063), a shorter delay 
between symptom recognition and arrival at hospital (p=0.0025), history of atrial fibrillation 
(p=0.19) were predictors of DWI-FLAIR mismatch in multivariate analysis.  
All other characteristics were comparable between groups. 
Conclusions – There are only minor differences in measured clinical characteristics between 
unknown symptom onset stroke patients with and without DWI-FLAIR mismatch. DWI-FLAIR 
mismatch as an indicator of stroke onset within 4.5 hours shows no relevant association with 
commonly collected clinical characteristics of stroke patients. 
Clinical Trial Registration – URL: http://www.clinicaltrials.gov. Unique identifier: 
NCT01525290; URL: https://www.clinicaltrialsregister.eu. Unique identifier: 2011-005906-32.  
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INTRODUCTION 
Information on the time of symptom onset plays a critical role in acute stroke treatment. 
Intravenous thrombolysis is approved for treatment within 4.5 hours of symptom onset, and 
for mechanical thrombectomy unequivocal evidence is also only available for treatment 
within the first six hours (1). In about 20% of acute stroke patients however, information on 
time of symptom onset is not available, e.g. because of patients waking up with stroke 
symptoms (2).  
Stroke MRI with diffusion weighted imaging (DWI) and fluid attenuated inversion recovery 
(FLAIR) imaging has been suggested as biomarker of ischemic lesion age (3). The DWI-
FLAIR mismatch, i.e. an acute ischemic lesion visible on DWI without corresponding 
parenchymal hyperintensity on FLAIR, was demonstrated to have a high positive predictive 
value in identifying patients within 4.5 hours of symptom onset in a multicentre study (4) as 
well as in several single centre studies from different groups (5-7). Case series using DWI-
FLAIR mismatch to guide intravenous thrombolysis or mechanical thrombectomy in unknown 
unset stroke patients have previously been published (8, 9).  
Using DWI-FLAIR mismatch as surrogate marker of lesion age relies on the assumption that 
time from symptom onset is the only relevant clinical factor influencing parenchymal 
hyperintensity on FLAIR and thus the presence or absence of DWI-FLAIR mismatch There 
is, however, hardly any data on potential clinical confounders of DWI-FLAIR mismatch in 
patients with unknown time of symptom onset. Thus, we aimed to identify possible clinical 
factors of influence on DWI-FLAIR mismatch by comparing clinical characteristics between 
patients with and without DWI-FLAIR mismatch in a large sample of patients with stroke of 
unknown onset.  
 
METHODS  
Study population 
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We analysed baseline data from the ongoing WAKE-UP trial (Efficacy and safety of MRI-
based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial; 
Clinicaltrials.gov identifier NCT01525290; EudraCT No.: 2011-005906-32) (10). In WAKE-UP 
MRI including DWI and FLAIR is used for screening stroke patients with unknown time of 
symptom onset, and patients presenting with DWI-FLAIR mismatch are randomized to 
treatment with intravenous thrombolysis or placebo. For this analysis we included baseline 
data of patients enrolled since the start of the trial on 22 September 2011 until 01 April 2016 
meeting the following criteria: (1) information on symptom recognition and demographic 
characteristics available; (2) acute ischemic lesion visible on DWI indicating acute cerebral 
ischemia; (3) judgement of DWI-FLAIR mismatch available; (4) no signs of intracerebral 
haemorrhage on MRI. 
 
DWI-FLAIR mismatch judgment 
DWI-FLAIR mismatch was judged by trial investigators according to image analysis 
standards outlined in the trial protocol and in additional training material. DWI-FLAIR 
mismatch is defined as the absence of a marked parenchymal hyperintensity in FLAIR in the 
region of a clearly visible acute DWI lesion, while subtle FLAIR hyperintensities are 
disregarded (10). Imaging handbooks provide detailed documentation of the imaging critiera 
and numerous example cases of the application of the imaging criteria in the trial (see figure 
for examples). All investigators judging brain images in WAKE-UP have completed a 
software-based image analysis training and passed a certification exam.  
 
Data analysis  
In order to identify clinical characteristics associated with the presence of DWI-FLAIR 
mismatch, univariate analysis was performed comparing patients with and without DWI-
FLAIR mismatch regarding the following clinical characteristics: age, sex, time between last 
seen normal and symptom recognition, delay between symptom recognition and hospital 
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arrival, reason for unknown time of symptom onset, neurological deficit on admission 
assessed by the National Institutes of Health Stroke Scale (NIHSS), medical history and 
vascular risk factors, current medication, presence of clinical exclusion criteria for 
thrombolysis. Fisher’s exact test or the Chi-square test was used for categorical variables, 
and non-parametric Kruskal-Wallis test was used for continuous variables. P<0.05 was 
considered significant in exploratory analysis without correction for multiple tests. 
Additionally, we performed a multivariate analysis using logistic regression model to predict 
the odd of DWI-FLAIR mismatch including all covariates with a p-value ≤0.15 in univariate 
analysis. Finally, only parameters with p<0.05 were retained. SAS software, version 9·3 
(SAS Institute Inc., Cary, NC) was used for all analyses. 
 
RESULTS 
Overall, 699 patients met the inclusion criteria. Of those 418 (59.8%) presented with DWI-
FLAIR mismatch and 281 (40.2%) hat no DWI-FLAIR mismatch. Results of group 
comparison are shown in the table. Patients with DWI-FLAIR mismatch had a shorter delay 
between last seen well and symptom recognition (median 7.5 vs. 8.0 h, p=0.0030).  A history 
of atrial fibrillation was more frequent in patients with a DWI-FLAIR (10.6% vs. 4.9%, 
p=0.0098). In multivariate analysis, both shorter delay between last seen well and symptom 
recognition with odds ratio (OR) 0.94 (95% confidence interval 0.91-0.98) and history of AF 
with OR 2.36 (1.11-5.02) were retained as significant predictors of DWI-FLAIR mismatch 
(see table). In addition, delay between symptom recognition and hospital arrival remained a 
significant predictor with OR 0.74 (0.62-0.90). All other characteristics were comparable 
between groups. 
 
DISCUSSION 
In this sample of acute stroke patients with unknown time of symptom onset, patients with 
DWI-FLAIR mismatch indicating symptom onset within 4.5 hours were comparable to 
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patients with no DWI-FLAIR mismatch with regards to the vast majority of clinical 
characteristics. There were no differences in age or severity of neurological symptoms 
reflected by the NIHSS score. There were also no differences concerning the majority of 
vascular risk factors, current medication, or the reason why symptom onset was not known. 
Two parameters differed between groups: the delay between last seen well and symptom 
recognition was shorter, and history of atrial fibrillation was more frequent in patients with 
DWI-FLAIR mismatch. 
This is the first analysis of clinical characteristics in a larger group of stroke patients with 
unknown time of symptom onset assumed to qualify for reperfusion treatment based on DWI-
FLAIR mismatch, and the results confirm the assumption that DWI-FLAIR mismatch as 
surrogate marker of lesion age is not strongly influenced by clinical characteristics of 
patients. This is in line with previous studies of DWI-FLAIR mismatch in patients with known 
symptom onset. In a large multicentre study, patients with DWI-FLAIR mismatch were 
mismatch were older but otherwise comparable to patients without a DWI-FLAIR 
mismatch(4). This, however, was discussed as a potential confounding effect of 
leukoaraiosis being more frequent with higher age and interacting with the visibility of acute 
ischemic lesions on FLAIR in the elderly. In WAKE-UP, severe leukoaraiosis interacting with 
the judgement of DWI-FLAIR mismatch is considered an exclusion criterion, which may 
obscure the indirect effect of age observed previously. 
With regards to the observed differences between the groups, findings have to be interpreted 
with caution as they only apply to patients eligible for this analysis which excluded patients 
with poor quality of MRI or severe leukoaraiosis precluding proper judgement of DWI.FLAIR 
mismatch.. However, the association of DWI-FLAIR mismatch with shorter delays between 
last seen well and symptom recognition and between symptom recognition and hospital 
arrival appears biologically plausible considering the visibility of acute ischemic lesions on 
FLAIR as a function of time. In all previous studies of DWI-FLAIR mismatch instroke patients 
with known onset, shorter time from symptom onset was the strongest predictor of DWI-
FLAIR mismatch (3-7). Although we do not know the time of stroke onset in our patients, it 
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may be reasonable to assume that a longer delay between last seen normal and symptom 
recognition may to a certain extent correlate with a longer delay between stroke onset and 
symptom recognition. 
The higher rate of atrial fibrillation in patients with DWI-FLAIR mismatch is less easily 
explained and may simply be due to chance. On the other hand, a circadian variation of atrial 
fibrillation with peak incidence in the morning hours (11) is known, and there are 
observations of a higher frequency of atrial fibrillation in wake-up stroke (12, 13). This might 
provide an explanation for a higher frequency of atrial fibrillation in those patients from our 
sample with stroke onset in the morning hours shortly before symptom recognition and thus 
more likely to show DWI-FLAIR mismatch. On the other hand, rates of atrial fibrillation were 
comparable between patients with wake-up stroke and those with unwitnessed daytime-
onset stroke (8.5% vs. 7.0%, p=0.16 Fisher’s exact test). 
Previous case series have reported on the rates of DWI-FLAIR mismatch in smaller samples 
with stroke of unclear onset as compared to patients with stroke of known onset, but they did 
not report on clinical characteristics of patients with DWI-FLAIR mismatch as compared to 
those without (14, 15). The proportion of patients with DWI-FLAIR mismatch in our 
population was slightly higher than in these two previous studies (59.8% as compared to 
43.7% and 50.0%), which may result from the fact that in within the context of WAKE-UP 
being a thrombolysis trial MRI may have been performed more rapidly, and that patients 
being clearly beyond the time window for thrombolysis, e.g. because of admission to hospital 
>4.5 hours of symptom recognition, were a priori excluded. The decreasing rate of DWI-
FLAIR mismatch with time passing appears to parallel decreasing proportions of patients 
with penumbral pattern with time from stroke onset (16). Although by concept DWI-FLAIR 
mismatch and penumbral imaging, e.g. perfusion-diffusion mismatch, address a different 
pathophysiological phenomenon, i.e. lesion age on the one hand and metabolic tissue status 
on the other hand, both imaging parameters appear to show a certain association 
independent from time fo stroke onset (17, 18). Future analyses of the subgroup of patients 
with perfusion MRI available in the WAKE-UP trial may further improve the understanding of 
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this association.To conclude, the MRI pattern of DWI-FLAIR mismatch was not associated 
with different clinical characteristics except for a longer delay and more frequent atrial 
fibrillation in the first 699 patients from our trial of intravenous thrombolysis in stroke with 
unknown symptom onset. Thus, DWI-FLAIR mismatch as indicator of stroke onset of less 
than 4.5 hours does not seem to be confounded by clinical characteristics of stroke patients 
beyond time from symptom onset and appears well suited as a surrogate marker of lesion 
age in patients with unknown time of symptom onset. The question of efficacy and safety of 
intravenous thrombolysis in unknown symptom onset stroke patients with DWI-FLAIR 
mismatch will be answered in the final analysis of the WAKE-UP trial. 
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TABLE 
Table: Group comparison of clinical characteristics  
 
 
DWI-FLAIR-
mismatch 
(n=418) 
No DWI-
FLAIR-
mismatch 
(n=281) 
Group 
comparison  
p-value 
Multivariate 
analysis  
p-value ‡ 
Age [years], median (IQR) 68 (59-74) 67 (58-74) 0.39 - 
Sex = female, n (%) 147 (35.2) 117 (41.6) 0.095 0.12 
Reason for unknown time of symptom 
onset 
Nigh-sleep wake-up stroke 
Daytime unwitnessed stroke 
 
368 (88.0) 
50 (12.0) 
 
240 (85.4) 
41 (14.6) 
0.15 0.93 
Delay between last seen well and 
symptom recognition [h], median (IQR) 
7.5 (5.0-9.0) 8.0 (6.0-10.0) 0.0030 0.0063 
Delay between symptom recognition and 
hospital arrival [h], median (IQR) 
1.6 (1.1-2.3) 1.8 (1.1-2.6) 0.11 0.0025 
Medical history / risk factors * 
Arterial hypertension, n (%) 
Diabetes mellitus, n (%) 
Hypercholesterolemia, n (%) 
Atrial fibrillation, n (%) 
Ischemic stroke, n (%) 
Transient ischemic attack, n (%) 
Intracranial haemorrhage, n (%) 
Gastrointestinal bleeding, n (%) 
 
200/415 (48.2) 
62/410 (15.1) 
120/391 (30.7) 
43/406 (10.6) 
59/415 (14.2) 
15/409 (3.7) 
0 
6/413 (1.5) 
 
134/266 (50.4) 
45/269 (16.7) 
68/259 (26.3) 
13/266 (4.9) 
26/270 (9.6) 
11/269 (4.1) 
0 
5/270 (1.9) 
 
0.58 
0.59 
0.25 
0.0098 
0.077 
0.84 
- 
0.76 
 
- 
- 
- 
0.019 
0.47 
- 
- 
- 
 
Smoking 
Never smoked, n (%) 
Ex-smoker, n (%) 
Current smoker, n (%) 
 
176/401 (43.9) 
108/401 (26.9) 
117/401 (29.2) 
 
98/245 (40.0) 
60/245 (24.5) 
87/245 (35.5) 
0.25 - 
 
Current medication * 
Antiplatelets, n (%) 
Anticoagulants, n (%) 
Antihypertensives, n (%) 
Antidiabetics, n (%) 
Statins, n (%) 
 
142/414 (34.1) 
4/415 (1.0) 
199/416 (47.8) 
54/416 (13.0) 
124/415 (30.0) 
 
72/264 (27.3) 
2/264 (0.8) 
141/264 (53.4) 
40/462 (15.2) 
76/264 (28.8) 
 
0.063 
1.00 
0.18 
0.43 
0.80 
 
0.26 
- 
- 
- 
- 
NIHSS on admission, median (IQR) 6 (4-11) 6 (4-12) 0.68 - 
Clinical exclusion criteria for IV-tPA 
treatment present, n (%) 
8 (1.9) 10 (3.6) 0.22 - 
* Percentage calculated with reference to number of patients with information available;  
† intracerebral haemorrhage, subarachnoid haemorrhage, intraventricular haemorrhage, hemorrhagic 
transformation;  
‡ parameters with p≤0.15 in univariate analysis were entered into multivariate logistic regression 
model 
IQR = interquartile range; NIHSS = National Institutes of Stroke Scale;  
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FIGURE 
 
 
 
 
FIGURE LEGEND 
Examples of DWI-FLAIR mismatch and No DWI-FLAIR mismatch.  
The figure shows three cases from the study sample. For each case, two representative 
slices of diffusion weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) 
are shown. (A) DWI-FLAIR mismatch – no parenchymal hyperintensity visible on FLAIR in 
the region of the acute DWI lesion, patient was randomized; (B) DWI-FLAIR mismatch – 
subtle parenchymal hyperintensity visible on FLAIR in the region of the acute DWI lesion 
considered as “negative” FLAIR according to the image judgement criteria in WAKE-UP, thus 
imaging criteria of DWI-FLAIR mismatch are met, patient was randomized; (C) No DWI-
FLAIR mismatch – clear parenchymal hyperintensity visible on FLAIR in the regions of acute 
DWI lesion, patient was not randomized.    
 
